|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Antioxidant therapy in the management of acute,chronic and post-ERCP pancreatitis:A systematic review显示文摘We systematically reviewed the clinical trials which recruited antioxidants in the therapy of pancreatitis and evaluated whether antioxidants improve the outcome of patients with pancreatitis.Electronic bibliographic databases were searched for any studies which investigated the use of antioxidants in the management of acute pancreatitis(AP)or chronic pancreatitis(CP)and in the prevention of post-endoscopic retrograde cholangio-pancreatography(post-ERCP)pancreatitis(PEP)up to February 2009.Twenty-two randomized,placebo-controlled,clinical trials met our criteria and were included in the review.Except for a cocktail of antioxidants which showed improvement in outcomes in three different clinical trials,the results of the administration of other antioxidants in both AP and CP clinical trials were incongruent and heterogeneous.Furthermore,antioxidant therapy including allopurinol and N-acetylcysteine failed to prevent the onset of PEP in almost all trials.In conclusion,the present data do not support a benefit of antioxidant therapy alone or in combination with conventional therapy in the management of AP,CP or PEP.Further double blind,randomized,placebo-controlled clinical trials with large sample size need to be conducted. | Seyed Sajad Mohseni Salehi Monfared Hamed Vahidi Amir Hossein Abdolghaffari Shekoufeh Nikfar Mohammad Abdollahi | 2009 | World Journal of Gastroenterology2009，15，36： | 10 |
| 2 | Antioxidant therapy in acute,chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis:An updated systematic review and meta-analysis显示文摘AIM:To investigate the efficacy and adverse effects of antioxidant therapy in acute pancreatitis(AP),chronic pancreatitis(CP) and post-endoscopic retrograde cholangiopancreatography pancreatitis(PEP).METHODS:Pub Med,Scopus,Google Scholar,Cochrane library database,and Evidence-based medicine/clinical trials published before August 2014 were searched. Clinical and laboratory outcomes of randomized trials of antioxidant therapy in patients with AP,CP and PEP were included. The methodological quality of the trials was assessed by the Jadad score based on the description of randomization,blinding,and dropouts(withdrawals). The results of the studies were pooled and meta-analyzed to provide estimates of the efficacy of antioxidant therapy.RESULTS:Thirty four trials out of 1069 potentially relevant studies with data for 4898 patients wereeligible for inclusion. Antioxidant therapy significantly reduced the length of hospital stay in AP patients {mean difference-2.59 d(95%CI:-4.25-(-0.93)],P = 0.002}. Although,antioxidant therapy had no significant effect on serum C reactive protein(CRP) after 5-7 d in AP patients [mean difference-9.57(95%CI:-40.61-21.48,P = 0.55],it significantly reduced serum CRP after 10 d {mean difference-45.16 [95%CI:-89.99-(-0.33)],P = 0.048}. In addition,antioxidant therapy had no significant effect on CP-induced pain [mean difference-2.13(95%CI:-5.87-1.6),P = 0.26]. Antioxidant therapy had no significant effects on the incidence of all types of PEP [mean difference 1.05(95%CI:0.74-1.5),P = 0.78],severe PEP [mean difference 0.92(95%CI:0.43-1.97),P = 0.83],moderate PEP [mean difference 0.82(95%CI:0.54-1.23),P = 0.33],and mild PEP [mean difference 1.33(95%CI:0.99-1.78),P = 0.06]. Furthermore,while antioxidant therapy had no significant effect on serum amylase after less than 8 h sampling [mean difference-20.61(95%CI:-143.61-102.39),P = 0.74],it significantly reduced serum amylase close to 24-h sampling {mean difference-16.13 [95%CI:-22.98-(-9.28)],P < 0.0001}.CONCLUSION:While there is some evidence to support antioxidant therapy in AP,its effect on CP and PEP is still controversial. | Maziar Gooshe Amir Hossein Abdolghaffari Shekoufeh Nikfar Parvin Mahdaviani Mohammad Abdollahi | 2015 | World Journal of Gastroenterology2015，21，30： | 6 |
| 3 | Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways显示文摘Inflammatory bowel disease(IBD)refers to a group of disorders characterized by chronic inflammation of the gastrointestinal(GI)tract.The elevated levels of nitric oxide(NO)in serum and affected tissues;mainly synthesized by the inducible nitric oxide synthase(iNOS)enzyme;can exacerbate GI inflammation and is one of the major biomarkers of GI inflammation.Various natural and synthetic agents are able to ameliorate GI inflammation and decrease iNOS expression to the extent comparable with some IBD drugs.Thereby,the purpose of this study was to gather a list of natural or synthetic mediators capable of modulating IBD through the NO pathway.Electronic databases including Google Scholar and PubMed were searched from 1980 to May 2018.We found that polyphenols and particularly flavonoids are able to markedly attenuate NO production and iNOS expression through the nuclear factorκB(NF-κB)and JAK/STAT signaling pathways.Prebiotics and probiotics can also alter the GI microbiota and reduce NO expression in IBD models through a broad array of mechanisms.A number of synthetic molecules have been found to suppress NO expression either dependent on the NF-κB signaling pathway(i.e.,dexamethasone,pioglitazone,tropisetron)or independent from this pathway(i.e.,nicotine,prednisolone,celecoxib,β-adrenoceptor antagonists).Co-administration of natural and synthetic agents can affect the tissue level of NO and may improve IBD symptoms mainly by modulating the Toll like receptor-4 and NF-κB signaling pathways. | Aida Kamalian Masoud Sohrabi Asl Mahsa Dolatshahi Khashayar Afshari Shiva Shamshiri Nazanin Momeni Roudsari Saeideh Momtaz Roja Rahimi Mohammad Abdollahi Amir Hossein Abdolghaffari | 2020 | World Journal of Gastroenterology2020，26，24： | 5 |
| 4 | Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis显示文摘AIM: To investigate the beneficial effect of the combination of butyrate, Lactobacillus casei, and L-carnitine in a rat colitis model.METHODS: Rats were divided into seven groups. Fourgroups received oral butyrate, L-carnitine, Lactobacillus casei and the combination of three agents for 10 consecutive days. The remaining groups included negative and positive controls and a sham group. Macroscopic, histopathological examinations, and biomarkers such as tumor necrosis factor-alpha(TNF-α) and interlukin-1β(IL-1β), myeloperoxidase(MPO), thiobarbituric acid reactive substances(TBARS), and ferric reduced ability of plasma(FRAP) were determined in the colon.RESULTS: The combination therapy exhibited a significant beneficial effect in alleviation of colitis compared to controls. Overall changes in reduction of TNF-α(114.66 ± 18.26 vs 171.78 ± 9.48 pg/mg protein, P < 0.05), IL-1β(24.9 ± 1.07 vs 33.06 ± 2.16 pg/mg protein, P < 0.05), TBARS(0.2 ± 0.03 vs 0.49 ± 0.04 μg/mg protein, P < 0.01), MPO(15.32 ± 0.4 vs 27.24 ± 3.84 U/mg protein, P < 0.05), and elevation of FRAP(23.46 ± 1.2 vs 15.02 ± 2.37 μmol/L, P < 0.05) support the preference of the combination therapy in comparison to controls. Although the monotherapies were also effective in improvement of colitis markers, the combination therapy was much better in improvement of colon oxidative stress markers including FRAP, TBARS, and MPO.CONCLUSION: The present combination is a suitable mixture in control of experimental colitis and should be trialed in the clinical setting. | Mahsa Moeinian Seyedeh Farnaz Ghasemi-Niri Shilan Mozaffari Amir Hossein Abdolghaffari Maryam Baeeri Mona Navaea-Nigjeh Mohammad Abdollahi | 2014 | World Journal of Gastroenterology2014，20，31： | 5 |
| 5 | New biologic therapeutics for ulcerative colitis and Crohn’s disease显示文摘 | Shilan Mozaffari Shekoufeh Nikfar Amir Hossein Abdolghaffari Mohammad Abdollahi | 2014 | Expert Opinion on Biological Therapy2014，，5： | 3 |
| 6 | On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators显示文摘 | Abdolghaffari Amir Hossein Baghaei Amir Moayer Fariborz Esmaily Hadi Baeeri Maryam Monsef-Esfahani Hamid Reza Hajiaghaee Reza Abdollahi Mohammad | 2010 | Human and Experimental Toxicology2010，，4： | 1 |
| 7 | Hypoxia/ischemia a key player in early post stroke seizures: Modulation by opioidergic and nitrergic systems显示文摘 | Maziar Gooshe Amir Hossein Abdolghaffari Ali Reza Aleyasin Leila Chabouk Sina Tofigh Gholam Reza Hassanzadeh Borna Payandemehr Alireza Partoazar Yaser Azizi Ahmad Reza Dehpour | 2015 | European Journal of Pharmacology2015，，： | 1 |
| 8 | New biologic thera- peutics for ulcerative colitis and Crohn's disease 显示文摘 | Mozaffari S Nikfar S Abdolghaffari AH | 2014 | Expert Opin Biol Ther2014，14，5： | 1 |
| 9 | On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators显示文摘 | Abdolghaffari Amir Hossein Baghaei Amir Moayer Fariborz Esmaily Hadi Baeeri Maryam Monsef-Esfahani Hamid Reza Hajiaghaee Reza Abdollahi Mohammad | 2010 | Human and Experimental Toxicology2010，，4： | 1 |
| 10 | On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators显示文摘 | Abdolghaffari Amir Hossein Baghaei Amir Moayer Fariborz Esmaily Hadi Baeeri Maryam Monsef-Esfahani Hamid Reza Hajiaghaee Reza Abdollahi Mohammad | 2010 | Human and Experimental Toxicology2010，，4： | 1 |
| 11 | Toll like receptors: a new hope on the horizon to treat multiple sclerosis 显示文摘 | Gooshe M Aleyasin AR Abdolghaffari AH | 2014 | Expert Rev Clin Immunol2014，10，10： | 1 |
| 12 | Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment显示文摘long-term,and relapsing inflammatory disorders.IBD may spontaneously grow in the colon,and in severe cases may result in tumor lesions such as invasive carcinoma in inflamed regions of the intestine.Recent epidemiological reports indicate that old age and underlying diseases such as IBD contribute to severity and mortality in patients with coronavirus disease 2019(COVID-19).Currently,the ongoing COVID-19 pandemic caused serious morbidity and mortality worldwide.It has also been shown that the transmembrane serine protease 2 is an essential factor for viral activation and viral engulfment.Generally,viral entry causes a'cytokine storm'that induces excessive generation of proinflammatory cytokines/chemokines including interleukin(IL)-6,IL-2,IL-7,tumor necrosis factor-α,and interferon-γ.Future research could concentrate on developing inflammatory immunological responses that are efficient to encounter COVID-19.Current analysis elucidates the role of inflammation and immune responses during IBD infection with COVID-19 and provides a list of possible targets for IBD-regulated therapies in particular.Data from clinical,in vitro,and in vivo studies were collected in English from PubMed,Google Scholar,Scopus,and the Cochrane library until May 2021. | Naser-Aldin Lashgari Nazanin Momeni Roudsari Saeideh Momtaz Amir Hossein Abdolghaffari | 2021 | World Journal of Gastroenterology2021，27，46： | 0 |
| 13 | Mammalian target of rapamycin;novel insight for management of inflammatory bowel diseases显示文摘Inflammatory bowel diseases(IBDs),with blurred etiology,show a rising trend and are of global concern.Of various factors involved in IBD pathogenesis and development,inflammation has been shown to play a major role.Recognition of the molecular and cellular pathways that induce IBD is an emerging subject to develop targeted therapies.Mammalian target of rapamycin(mTOR)is one the most common receptors of many inflammatory pathways,including that of IBD.To this end,we intend to overview the mTOR inhibitors for their possible efficacy in present and future approaches to treatment of IBD. | Naser-Aldin Lashgari Nazanin Momeni Roudsari Saeideh Momtaz Amir Hossein Abdolghaffari | 2022 | World Journal of Pharmacology2022，11，1： | 0 |
| 14 | The protective effect of a standardized hydroalcoholic extract of Prosopis farcta (Banks & Sol.) J.F.Macbr. fruit in a rat model for experimental ulcerative colitis显示文摘Background:Investigating new therapies for inflammatory bowel disease among natural products has recently been gaining attention.Although Prosopis farcta has repeatedly been mentioned in traditional Persian medicine as a therapeutic option for inflammatory bowel disease,no evidence-based investigations have been conducted on this topic.The aim of this study was to assess the impact of P.farcta on acetic acid-induced colitis in rats.Methods:A hydroalcoholic extract of P.farcta fruits was prepared.Thirty-six adult Wistar rats were divided into six groups,and colitis was induced in five groups,except the sham group,using acetic acid solution.The animals received distinctive daily doses of P.farcta(50,75,and 100 mg/kg/day,p.o.)and dexamethasone(1 mg/kg/day,i.p.)as standard treatment for two progressive days,starting from colitis induction.Microscopic and histopathological examinations were performed on inflamed colonic tissue.Tissue concentrations of interleukin-1βand tumor necrosis factor-αwere assessed using enzyme-linked immunosorbent assay kits.To identify the role of oxidative stress in ulcerative colitis,the levels of malondialdehyde and myeloperoxidase were measured in colon tissues.Results:Treatment with all concentrations of P.farcta attenuated inflammation and ulcers compared with saline treatment in the control group(P<0.01 for 50 mg/kg;P<0.001 for 75 and 100 mg/kg/day).The best suppression of tumor necrosis factor-αand interleukin-1βwas observed at a dose of 100 mg/kg P.farcta(P<0.001).This dose showed the best effect in reducing myeloperoxidase and malondialdehyde in ulcerative colitis-induced rats(P<0.001).Conclusion:P.farcta can be considered a promising candidate for treating ulcerative colitis;thus,it requires further confirmation by clinical trials. | Ali Akbar Safari Mohammad Sharifzadeh Gholamreza Hassanzadeh Mohammad-Reza Delnavazi�� Mohammad Mahdi Ahmadian-Attari Amir Hossein Abdolghaffari Maryam Baeeri Mehran Mirabzadeh Ardakani | 2021 | Traditional Medicine Research2021，6，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员